Research Topics
Genomes and Genes | Paul S AisenSummaryAffiliation: Georgetown University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2Lauren Spielman
Neuroinflammation Research Laboratories, Department of Psychiatry, Box 1229, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
Acta Neuropathol 103:157-62. 2002..Because there is extensive evidence that C1q and other complement components are involved in Alzheimer's disease (AD) neurodegeneration, this study advances our understanding of the apparent benefits of COX-2 inhibition in AD...- Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trialPaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
JAMA 289:2819-26. 2003.... - The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitorsPaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington DC, USA
CNS Drugs 19:989-96. 2005..Thus, it is plausible that an effective anti-amyloid strategy will become available for the treatment of Alzheimer's disease within the next few years... - Leon Thal and the therapeutic age of Alzheimer's diseasePaul S Aisen
University of California San Diego, San Diego, CA, USA
Alzheimers Dement 4:S4-6. 2008 - Alzhemed: a potential treatment for Alzheimer's diseasePaul S Aisen
Department of Neurology, Georgetown University, Washington, DC 20057, USA
Curr Alzheimer Res 4:473-8. 2007..These findings will be discussed in the context of two large-scale randomized, double-blind, placebo-controlled Phase III clinical trials that are currently being conducted to test the long-term safety and efficacy of Alzhemed... - The potential of anti-inflammatory drugs for the treatment of Alzheimer's diseasePaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington DC 20007, USA
Lancet Neurol 1:279-84. 2002..Several studies, including a large primary prevention trial with NSAIDs, are still in progress. Major issues of selection of patients, drug regimen, and duration of treatment remain unresolved... - Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognitionP S Aisen
Department of Neurology, Georgetown University Medical Center, 1Bles Building, 3800 Reservoir Road NW, Washington, DC 20007, USA
Psychoneuroendocrinology 28:113-20. 2003..These results support a relationship between gender, apolipoprotein E genotype and glucose metabolism, but do not indicate that mild changes in glucose have an important impact on cognitive function... - Anti-inflammatory agents in Alzheimer's diseasePaul S Aisen
Department of Neurology, Georgetown University Medical Center, 3800 Reservoir Road NW, 1 Bles Building, Washington, DC 20057, USA
Curr Neurol Neurosci Rep 2:405-9. 2002.... - Randomized pilot study of nimesulide treatment in Alzheimer's diseaseP S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
Neurology 58:1050-4. 2002..Clinical and laboratory experience with nimesulide, an NSAID with preferential cyclooxygenase-2 inhibition, suggests that it may be a good candidate for AD therapy... 
Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivoChiho Hirata-Fukae
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
Neurosci Lett 450:51-5. 2009..Taken together, these findings suggest that levels of soluble and insoluble tau are indicative of overall levels of tau phosphorylation, and may be useful markers to evaluate the effects of anti-tau therapeutic strategies in vivo...
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tauRahul S Desikan
Department of Radiology, University of California San Diego, 8950 Villa La Jolla Dr, Ste C101, La Jolla, CA 92037 0841, USA
Arch Neurol 69:709-13. 2012..To elucidate the relationship between the 2 hallmark proteins of Alzheimer disease (AD), amyloid-(Aβ) and tau, and clinical decline over time among cognitively normal older individuals...- Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairmentDanielle C Whitehair
Department of Neurosciences, University of California, San Diego, CA, USA
Alzheimers Dement 6:412-9. 2010..We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI)... - Amyloid-β associated volume loss occurs only in the presence of phospho-tauRahul S Desikan
Department of Radiology, University of California San Diego, La Jolla 92037, CA
Ann Neurol 70:657-61. 2011..Our findings indicate that Aβ-associated volume loss occurs only in the presence of phospho-tau in humans at risk for dementia... - Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic modelChiho Hirata-Fukae
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
Brain Res 1216:92-103. 2008..These findings confirm progressive Abeta pathology in 3xTg-AD transgenic mice, and provide guidance for their use in therapeutic research... - 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjectsLiana G Apostolova
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
Neurobiol Aging 31:1284-303. 2010..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy... - Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trialPaul S Aisen
Georgetown University Medical Center, Washington, DC, USA
Curr Alzheimer Res 5:73-82. 2008..The significance of the observation that rofecoxib increased the rate of conversion from MCI to AD remains uncertain... - Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trialJoseph F Quinn
Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
JAMA 304:1903-11. 2010..Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology... - 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCILiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
Hum Brain Mapp 31:786-97. 2010..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses... - The Alzheimer's disease neuroimaging initiative: progress report and future plansMichael W Weiner
Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center, San Francisco, CA, USA
Alzheimers Dement 6:202-11.e7. 2010..All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD... - Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's diseaseDavid A Wolk
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
Proc Natl Acad Sci U S A 107:10256-61. 2010.... - Clinical and biomarker changes in dominantly inherited Alzheimer's diseaseRandall J Bateman
Washington University School of Medicine, Department of Neurology, 660 S Euclid Ave, Box 8111, St Louis, MO 63110, USA
N Engl J Med 367:795-804. 2012..Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease... - The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inceptionMichael W Weiner
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
Alzheimers Dement 8:S1-68. 2012..The ADNI study was extended by a 2-year Grand Opportunities grant in 2009 and a renewal of ADNI (ADNI-2) in October 2010 through to 2016, with enrollment of an additional 550 participants... - Agreement in cognitive and clinical assessments in Alzheimer's diseaseRochelle E Tractenberg
Departments of Neurology, Biostatistics, Bioinformatics and Biomathematics, and Psychiatry, Georgetown University School of Medicine, Washington, D C 20057, USA
Dement Geriatr Cogn Disord 27:344-52. 2009..To estimate agreement among scores on three common assessments of cognitive function... - A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's diseaseYasuji Matsuoka
Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Road N W, Washington, DC 20057, USA
J Pharmacol Exp Ther 325:146-53. 2008..Our results suggest that neuronal microtubule interacting agents such as NAP may be useful therapeutic agents for the treatment or prevention of tauopathies... - NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementiaSteven D Edland
Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
Alzheimer Dis Assoc Disord 24:159-64. 2010..Targeted retention efforts and utilization of academic sites could substantively improve the statistical power and validity of future clinical trials of cognitively impaired elderly... - ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI)Sally P Walsh
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
Alzheimer Dis Assoc Disord 20:S170-8. 2006.... - High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trialPaul S Aisen
Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
JAMA 300:1774-83. 2008..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline... - Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivoChiho Hirata-Fukae
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
Neurosci Lett 435:186-9. 2008..Further, these results suggest that substantial inhibition of BACE1 in brain may be required for clinical benefit in Alzheimer's disease... - Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plansPaul S Aisen
Department of Neurosciences, University of California San Diego, CA, USA
Alzheimers Dement 6:239-46. 2010..The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations... - Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer diseaseLinda K McEvoy
Department of Radiology, University of California, San Diego, La Jolla, CA 92093 0841, USA
Alzheimer Dis Assoc Disord 24:269-77. 2010..Failure to take into account normal age-related changes risks under-powering trials designed to test disease-modifying properties of potential treatments... - Safety and biomarker effects of solanezumab in patients with Alzheimer's diseaseMartin Farlow
Department of Neurology, Indiana University School of Medicine, Indianapolis, USA
Alzheimers Dement 8:261-71. 2012..Cognitive measures were also obtained... - Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 yearsR Scott Mackin
Department of Psychiatry, University of California, San Francisco, CA, USA
Int J Geriatr Psychiatry 27:355-63. 2012..To evaluate the degree to which longitudinal stability of subsyndromal symptoms of depression (SSD) is associated with conversion to dementia in patients with mild cognitive impairment (MCI)... - Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseReisa A Sperling
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Alzheimers Dement 7:280-92. 2011.... - MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study populationRema Raman
Department of Neurosciences, University of California San Diego, La Jolla, 92093 0717, USA
Alzheimer Dis Assoc Disord 23:333-6. 2009..To determine if a self-selected group of participants who enroll in an imaging substudy of Alzheimer disease (AD) clinical trials is representative of the overall study sample... - Applications of neuroimaging to disease-modification trials in Alzheimer's diseaseAdam S Fleisher
Department of Neurosciences, University of California, San Diego, USA
Behav Neurol 21:129-36. 2009..This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD... - Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stageYasuji Matsuoka
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
J Mol Neurosci 31:165-70. 2007..Our results indicate that NAP treatment of transgenic mice initiated at an early stage reduced both Abeta and tau pathology, suggesting that NAP might be a potential therapeutic agent for AD... - Nonlinear time course of brain volume loss in cognitively normal and impaired eldersNorbert Schuff
Center for Imaging of Neurodegenerative Diseases and VA Medical Center, San Francisco, CA, USA
Neurobiol Aging 33:845-55. 2012..The approach has potential uses for early detection of AD and differentiation between stable and progressing MCI... - Plasma urate and progression of mild cognitive impairmentMichael C Irizarry
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
Neurodegener Dis 6:23-8. 2009..Impaired antioxidant defenses are implicated in neurodegenerative disease. The plasma levels of urate, a water-soluble antioxidant, are reduced in Alzheimer's disease (AD)... - The relationship of plasma Abeta levels to dementia in aging individuals with Down syndromeYasuji Matsuoka
Department of Neurology, Georgetown University Medical Center, Washington, DC, USA
Alzheimer Dis Assoc Disord 23:315-8. 2009.... - A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer diseasePaul S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
Am J Geriatr Psychiatry 11:246-9. 2003..CONCLUSION: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study... - Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
Arch Neurol 61:59-66. 2004..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD... - Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer diseaseAdam S Fleisher
University of California, San Diego, La Jolla, CA 92037, USA
Arch Neurol 65:1031-8. 2008..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease... - One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive declineRochelle E Tractenberg
Department of Biomathematics and Biostatistics, Georgetown University School of Medicine, Washington, DC, USA
Am J Alzheimers Dis Other Demen 20:239-47. 2005.... - Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost"Rochelle E Tractenberg
Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, United States of America
PLoS ONE 7:e30019. 2012..We found that measurement error, as we defined it, was inconsistent over time and across cognitive functioning levels, violating the theory underlying reliability and other psychometric characteristics, and key regression assumptions... - Clinical trial methodologies for disease-modifying therapeutic approachesPaul S Aisen
Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA
Neurobiol Aging 32:S64-6. 2011..Data suggest that neuroimaging biomarkers will be useful as endpoints for trials in very early, even asymptomatic disease, though further work is necessary to establish validity for regulatory purposes... - Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)Paul S Aisen
University of California, San Diego, La Jolla, CA, USA
Arch Med Sci 7:102-11. 2011..The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMED(TM)) in mild-to-moderate Alzheimer's disease (AD)... - A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderlyApril J Ho
Laboratory of Neuroimaging, Department of Neurology, University of California School of Medicine, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 107:8404-9. 2010..These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly... - No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's diseaseRochelle E Tractenberg
Department of Neurology, Georgetown University School of Medicine, Washington, DC, USA
Neurobiol Aging 30:1327-8. 2009..No significant influence of epsilon4 was detected. APOE's effect in AD may occur prior to clinical symptoms, or may simply be more subtle than these instruments can detect... - Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's diseasePaul S Aisen
Departments of Neurology and Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
J Pain Symptom Manage 23:S35-40. 2002..This study, along with other clinical studies currently under way, will determine the utility of selective and nonselective COX inhibitors for the prevention and treatment of AD... - Antibody against C-terminal Abeta selectively elevates plasma AbetaAudrey J Gray
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
Neuroreport 18:293-6. 2007..In this study, we found that anti-amyloid beta 40-specific antibody induces amyloid beta sequestration. These results indicate that C-terminal antibodies may be useful in amyloid beta sequestration therapy... - Georgetown University School of MedicinePamela A Saunders
Acad Med 79:S45-50. 2004 - Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trialP S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
Acta Neurol Scand Suppl 176:85-9. 2000..The ADCS has initiated a trial to determine whether treatment with a non-selective non-steroidal anti-inflammatory drug or a selective cyclooxygenase-2 inhibitor is effective in slowing the rate of cognitive decline in AD... - Inflammatory processes and Alzheimer's diseaseSally Walsh
Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
Expert Rev Neurother 4:793-8. 2004..It is concluded that such treatments should not be recommended, although additional investigation is warranted... - A simple method to rule out dementia with temporal orientationRochelle E Tractenberg
Department of Neurology, Georgetown University, Washington, DC, USA Departments of Biostatistics, Bioinformatics and Biomathematics and Psychiatry, Georgetown University School of Medicine, Washington, DC, USA
Alzheimers Dement 3:28-32. 2007..Prospective validation of the TTO is warranted... - Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairmentA S Fleisher
Department of Neurosciences, University of California, San Diego, CA, USA
Neurology 70:191-9. 2008..To compare volumetric MRI of whole brain and medial temporal lobe structures to clinical measures for predicting progression from amnestic mild cognitive impairment (MCI) to Alzheimer disease (AD)... - Longitudinal plasma amyloid beta as a biomarker of Alzheimer's diseaseRobert A Rissman
Alzheimer s Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA 92037 0624, USA
J Neural Transm 119:843-50. 2012..In this review, we discuss recent data on plasma β-amyloid (Aβ) and examine the issues that have arisen in establishing it as a reliable biomarker of AD... - Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderlyRochelle E Tractenberg
Department of Biomathematics and Biostatistics, Georgetown University School of Medicine, Washington, DC 20008, USA
Neuroepidemiology 24:110-6. 2005..TTO may be a useful component of cognitive screening efforts... - An update on huperzine A as a treatment for Alzheimer's diseaseJohn T Little
Georgetown University Hospital, Department of Psychiatry, 3800 Reservoir Road, NW, Kober Cogan 604, Washington, DC 20007, USA
Expert Opin Investig Drugs 17:209-15. 2008..This paper reviews the development of huperzine A as a treatment for AD, including the Phase II trial now under way in the US... - A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer diseaseP S Aisen
Department of Neurology, Georgetown University Medical Center, Washington, DC, USA
Neurology 67:1757-63. 2006..CONCLUSION: Long-term administration of 3-amino-1-propanesulfonic acid is safe, tolerated and reduces CSF Abeta(42) levels in patients with mild-to-moderate Alzheimer disease... - Recent developments in Alzheimer's disease therapeuticsMichael S Rafii
Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
BMC Med 7:7. 2009..In this review, we briefly discuss the current status of Alzheimer's disease therapies under study, as well the scientific context in which they have been developed... - Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseRandall J Bateman
Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
Alzheimers Res Ther 3:1. 2011..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention... - Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterizationR C Petersen
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Neurology 74:201-9. 2010..Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally... - ADCS Prevention Instrument Project: overview and initial resultsSteven H Ferris
Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
Alzheimer Dis Assoc Disord 20:S109-23. 2006..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles... - Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled studyRachelle S Doody
Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
Lancet 372:207-15. 2008..More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease... - BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type miceKouhei Nishitomi
Pain and Neurology, Discovery Research Laboratories, Shionogi Co. Ltd, Shiga, Japan
J Neurochem 99:1555-63. 2006..Studies using our new ELISA in non-transgenic mice provide more accurate evaluation of Abeta-reducing strategies than was previously feasible... - Pharmacologic treatment options in Alzheimer's disease: optimizing disease managementPaul S Aisen
J Am Acad Nurse Pract . 2005..In addition, memantine and a ChEI appear to produce an additive effect resulting in a well-tolerated, effective treatment strategy... - Tarenflurbil: a shot on goalPaul S Aisen
Lancet Neurol 7:468-9. 2008 - The inflammatory hypothesis of Alzheimer disease: dead or alive?Paul S Aisen
Alzheimer Dis Assoc Disord 22:4-5. 2008 - Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to somanRichard K Gordon
Walter Reed Army Institute of Research, Division of Biochemistry, 503 Robert Grant Rd, Silver Spring, MD 20910 7500, USA
Chem Biol Interact 157:239-46. 2005..The WRAIR WB ChE assay will fulfill the requirement for rapid and reliable monitoring of such exposure in military and civilian populations... - NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)Illana Gozes
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
CNS Drug Rev 11:353-68. 2005..NAP is poised for further clinical development targeting several indications, including Alzheimer's disease... - NSAIDs and hypertensionPaul S Aisen
Arch Intern Med 163:1115; author reply 1115-6. 2003 - Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestrationKazuyuki Takata
Department of Neurobiology, Kyoto Pharmaceutical University and 21st Century COE Program, Kyoto 607 8414, Japan
Eur J Neurosci 26:2458-68. 2007..We conclude that deglycosylated antibodies effectively induced Abeta sequestration without provoking neuroinflammation; thus, these deglycosylated antibodies may be optimal for sequestration therapy for Alzheimer's disease... - Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathologyZhongmin Xiang
Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA
Neurobiol Aging 23:327-34. 2002.... - Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variantYuko Horikoshi
Immuno-Biological Laboratories Co, Ltd, Fujioka-Shi, Gunma 375-0005, Japan
Biochem Biophys Res Commun 319:733-7. 2004..A combination of C-termini antibodies and an antibody against the middle region of Abeta detects mouse Abeta in non-transgenic mouse brains... - An aspirin a day for Alzheimer's disease?Paul S Aisen
Lancet Neurol 7:20-1. 2008 - Treatment for MCI: is the evidence sufficient?Paul S Aisen
Neurology 70:2020-1. 2008